

<b>REVOCATION OF PREVIOUS POWER OF ATTORNEY, APPOINTMENT OF NEW POWER OF ATTORNEY OR AUTHORIZATION OF AGENT, AND CHANGE OF CORRESPONDENCE ADDRESS</b>	Application Number	10/593,259
	Filing Date	03/18/05
	First Named Inventor	Remo KRANICH
	Title	Non-Glycosylated/Non-Glycosidic/Non-Peptidic Small Molecule PSGL-1 Mimetics for the Treatment of Inflammatory Disorders
	Group Art Unit	Unassigned
	Examiner Name	Unassigned
	Attorney Docket Number	045463-5000

I hereby revoke all previous powers of attorney or authorizations of agent given in the above-identified application and appoint:

☒ Practitioners at Customer Number

22204

*Place Customer  
Number Bar Code  
Label here*

☐ Practitioner(s) named below

Name	Registration Number

as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.

Please change the correspondence address for the above-identified application to:

☒ The above-mentioned Customer Number

**OR**

☐ Practitioners at Customer Number

*Place Customer  
Number Bar Code  
Label here*

**OR**

☐ Firm or  
Individual Name

Address

Address

City

State

Zip

Country

Telephone

Fax

I am the:

☐ Applicant/Inventor.

☒ Assignee of record of the entire interest according to the assignment and merger documents recorded at Reel/Frame 019608/0697 on July 25, 2007.

**SIGNATURE of Applicant or Assignee of Record**

Name

Signature

Date

NOTE: Signatures of all the inventors or assignees of record of the entire interest of their representative(s) are required. Submit multiple forms if more than one signature is required, see below\*.

☐ \*Total of \_\_\_\_\_ forms are submitted.

SEND TO: Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**STATEMENT UNDER 37 CFR 3.73(b)**Applicant/Patent Owner: Remo Kranich and Ewald Mirko AydtApplication No./Patent No.: 10/593,259 Filed/Issue Date: March 18, 2005Entitled: Non-Glycosylated/Non-Glycosidic/Non-Peptidic Small Molecule PSGL-1 Mimetics for the Treatment of Inflammatory DisordersRevotar Biopharmaceuticals AG, a corporation

(Name of Assignee)

(Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. ☒ the assignee of the entire right, title, and interest; or
2. ☐ an assignee of less than the entire right, title and interest.  
The extent (by, percentage) of its ownership interest is \_\_\_\_\_ %

in the patent application/patent identified above by virtue of either:

- A. ☒ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel 019608, Frame 0697 or for which a copy thereof is attached.

OR

- B. ☐ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:

1. From: \_\_\_\_\_ To: \_\_\_\_\_  
The document was recorded in the United States Patent and Trademark Office at Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.
2. From: \_\_\_\_\_ To: \_\_\_\_\_  
The document was recorded in the United States Patent and Trademark Office at Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.
3. From: \_\_\_\_\_ To: \_\_\_\_\_  
The document was recorded in the United States Patent and Trademark Office at Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.

- ☐ Copies of assignments or other documents in the chain of title are attached.

[NOTE: A separate copy (i.e., the original assignment document or true copy of the original document) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

29.02.2008

Date

Stephan Jarlac

Typed or printed name

Signature

Vorstand (CEO)

Title